Live virus vaccines in transplantation: friend or foe?
|Published in||Current Infectious Disease Reports. 2015, vol. 17, no. 4, p. 472|
|Abstract||Solid organ and hematopoietic stem cell transplant recipients may be exposed to diseases which may be prevented through live attenuated virus vaccines (LAVV). Because of their immunosuppression, these diseases can lead to severe complications in transplant recipients. Despite increasing evidence regarding the safety and effectiveness of certain LAVV, these vaccines are still contraindicated for immunocompromised patients, such as transplant recipients. We review the available studies on LAVV, such as varicella zoster, measles-mumps-rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. We discuss the current recommendations and the potential risks, as well as the expected benefits of LAVV immunization in this population.|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||Groupe Posfay-Barbe Clara (pédiatrie générale) (853)|
|VEROLET, Charlotte, POSFAY BARBE, Clara. Live virus vaccines in transplantation: friend or foe?. In: Current Infectious Disease Reports, 2015, vol. 17, n° 4, p. 472. https://archive-ouverte.unige.ch/unige:76147|